Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · IEX Real-Time Price · USD
7.09
+0.03 (0.42%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Cabaletta Bio Employees
As of December 31, 2023, Cabaletta Bio had 103 total employees, including 101 full-time and 2 part-time employees. The number of employees increased by 43 or 71.67% compared to the previous year.
Employees
103
Change (1Y)
43
Growth (1Y)
71.67%
Revenue / Employee
n/a
Profits / Employee
-$746,291
Market Cap
342.28M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 103 | 43 | 71.67% |
Dec 31, 2022 | 60 | 6 | 11.11% |
Dec 31, 2021 | 54 | 20 | 58.82% |
Dec 31, 2020 | 34 | 12 | 54.55% |
Dec 31, 2019 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Nevro | 1,215 |
uniQure | 480 |
Talkspace | 472 |
Xeris Biopharma Holdings | 377 |
ADC Therapeutics | 274 |
Sight Sciences | 214 |
Vanda Pharmaceuticals | 203 |
AC Immune | 161 |
CABA News
- 20 days ago - Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum - GlobeNewsWire
- 5 weeks ago - Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 - GlobeNewsWire
- 2 months ago - Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 4 months ago - Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Cabaletta Bio to Participate in Upcoming Investor Conferences in March - GlobeNewsWire
- 6 months ago - Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis - GlobeNewsWire
- 6 months ago - Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - GlobeNewsWire